Recent News

• 07.22.2025 - Carl Byrnes
• 07.22.2025 - Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
• 07.21.2025 - Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
• 07.18.2025 - Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
• 07.17.2025 - Boris Peaker
• 07.17.2025 - Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 07.09.2025 - Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
• 06.13.2025 - Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
• 06.05.2025 - Jefferies Healthcare Conference
• 06.04.2025 - Noble Capital Markets Virtual Conference

Recent Filings

• 07.21.2025 - 8-K Current report
• 07.21.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 07.18.2025 - F-6 POS Post-effective amendments for immediately effective filing
• 07.17.2025 - 8-K Current report
• 07.09.2025 - EX-99.1 EX-99.1
• 07.09.2025 - 8-K Current report
• 06.26.2025 - EFFECT Notice of Effectiveness
• 06.11.2025 - 144 Report of proposed sale of securities
• 06.10.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 06.10.2025 - F-3 Registration statement by foreign private issuers